Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Alexander Cole

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 7, 2009
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1Gregory A Grabowski, Katherine Kacena, J Alexander Cole, et al.
BMC Nephrology|December 15, 2015
The global aHUS registry: methodology and initial patient characteristicsChristoph Licht, Gianluigi Ardissino, Gema Ariceta, et al.
Molecular Genetics and Metabolism|January 10, 2012
Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry RegistryWilliam R Wilcox, Gabor E Linthorst, Dominique P Germain, et al.
British Journal of Haematology|May 30, 2012
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 yearsCarla E M Hollak, Nadia Belmatoug, J Alexander Cole, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 25, 2013
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry RegistryDominique P Germain, Frank Weidemann, Ademola Abiose, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 7, 2009
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1Gregory A Grabowski, Katherine Kacena, J Alexander Cole, et al.
BMC Nephrology|December 15, 2015
The global aHUS registry: methodology and initial patient characteristicsChristoph Licht, Gianluigi Ardissino, Gema Ariceta, et al.
Molecular Genetics and Metabolism|January 10, 2012
Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry RegistryWilliam R Wilcox, Gabor E Linthorst, Dominique P Germain, et al.
British Journal of Haematology|May 30, 2012
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 yearsCarla E M Hollak, Nadia Belmatoug, J Alexander Cole, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 25, 2013
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry RegistryDominique P Germain, Frank Weidemann, Ademola Abiose, et al.
Pageof 3